TEUM yields 2000000.00% · MRK yields 2.76%● Live data
📍 TEUM pulled ahead of the other in Year 1
Combined, TEUM + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TEUM + MRK for your $10,000?
Pareteum Corporation, a cloud software communications platform company, provides communications platform-as-a-service (CPaaS) solutions in the United States and internationally. Its platform offers mobility, messaging, and connectivity and security services and applications. The company's platform hosts integrated IT/back office and core network functionality for mobile network operators, as well as for enterprises to implement and leverage mobile communications solutions on a software-as-a-service (SaaS), PaaS, and/or infrastructure-as-a-service basis. It also delivers operational support system for channel partners with application program interfaces for integration with third party systems, workflows for complex application orchestration, and customer support with branded portals and plug-ins for various other applications. In addition, the company provides software solutions, which layer over disparate fixed, mobile, and IP networks to enable the deployment of converged communication services and applications for enterprise communications and core telecommunications markets; and Wi-Fi access on mobile devices through its SaaS platform. It serves the markets of Internet of Things, smart cities, and application developers, as well as mobile virtual network operators, enablers and aggregators. The company was formerly known as Elephant Talk Communications Corp. and changed its name to Pareteum Corporation in November 2016. The company was incorporated in 1962 and is headquartered in New York, New York. On May 15, 2022, Pareteum Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Full TEUM Calculator →Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.